Introduction©
In genetic research, the gold standard for confirming pathogenicity is a perfect match between an in silico prediction and an in vitro experimental validation. A recent study on Stickler syndrome type I (STL1) demonstrates the exceptional value of the RDDC bioinformatics tool in this critical process. In this study, RDDC not only successfully predicted multiple potential outcomes for a novel COL2A1 gene splicing variant, but its specific "exon 10 skipping" prediction was also highly consistent with the results of a subsequent minigene assay, providing decisive evidence for the variant's pathogenicity.
The Clinical Challenge: An Unproven Splice Site Variant
The study began with a neonate presenting with cleft palate, small mandible, and feeding difficulties, all classic symptoms of Stickler syndrome. The research team used trio-Whole Exome Sequencing (WES) and identified a de novo heterozygous variant in intron 9 of the COL2A1 gene: c.655-2A>G.
This variant, located at a canonical splice site, was absent from large population databases like gnomAD. Although other tools like SpliceAI predicted it to be highly pathogenic (ΔScore=1.00), this score alone could not reveal how it disrupted mRNA splicing or which aberrant transcript would be produced. Functional experiments were required.
RDDC's Precise Prediction and Experimental Validation
Before committing to time-consuming wet-lab experiments, the research team utilized the RDDC tool for a more precise forecast. The RDDC analysis provided three specific, testable hypotheses for abnormal splicing patterns:
- Exon skipping
- Intron retention
- Base deletion
Significantly, one of RDDC's predicted modes was the "skipping of exon 10 (a 54 bp deletion)".
Experimental Validation
To validate this in silico prediction, the team constructed a minigene model for in vitro testing. The experimental results were clear: the c.655-2A>G variant caused the complete skipping of exon 10 from the COL2A1 mRNA.
Closing the Loop from Prediction to Proof
This experimental finding was in perfect agreement with the "exon 10 skipping" pattern predicted by RDDC. This 54 bp deletion, precisely forecasted by RDDC and confirmed by the assay, would lead to the loss of 18 amino acids in the final type II collagen protein, thus disrupting its normal structure and confirming its pathogenicity.
This case powerfully demonstrates that RDDC is more than a prediction tool; it is a reliable guide for experimental design. By providing specific, verifiable hypotheses for splicing patterns, it helps researchers dramatically shorten the cycle from variant discovery to mechanism elucidation, making it a powerful partner for analyzing non-coding variants and improving the efficiency of rare disease diagnostics.
Content Source and Disclaimer
This article is a compilation and interpretation of the scientific study cited below, intended to highlight the application of RDDC bioinformatics tools. All research data and conclusions belong to the original authors and publication.
Original Article
Luo J, Zhao C, Sun J, et al. Identification and functional characteristics of a novel splicing heterozygote variant of COL2A1 associated with Stickler syndrome type I. Clinical Chimica Acta. 2023 Nov 1;550:117578.
Article Link: https://pubmed.ncbi.nlm.nih.gov/39050257/
